SanofiSNY stock plummeted Thursday after the company's experimental eczema drug proved meaningfully inferior to Dupixent, a ...

Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Eczema affects 1 in 5 infants and can lead to allergies and asthma later. Dr. Elisa Song, chief medical officer at Tiny Health, explains study on how parents can help prevent baby eczema.

Doctors have shared their top tips for travelling with eczema, offering some wise words for people who find heading to ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

A trial of Sanofi’s new eczema drug has disappointed investors hoping for a replacement for its blockbuster Dupixent, sending the French pharma group’s shares down more than 9 per cent on Thursday.

First FDA-approved medication for atopic dermatitis (eczema), plaque psoriasis, and seborrheic dermatitis to win prominent “Breakthrough ...

World Atopic Eczema Day 2025 calls for early intervention, better care and greater awareness of the hidden toll of atopic ...

Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in ...